Adrenomedullin Pegol - Bayer Healthcare
Alternative Names: BAY-1097761; Peg adrenomedullin; PEG-ADM inhalation; PEGylated adrenomedullinLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Bayer HealthCare
- Class Peptides; Polyethylene glycols; Vasodilators
- Mechanism of Action Adrenomedullin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Adult respiratory distress syndrome
Most Recent Events
- 18 Apr 2023 Bayer HealthCare terminates a phase II trial in Adult respiratory distress syndrome in Austria, Czech Republic, Germany, Spain, France and Italy based on Part A results, the company decided to not continue investigating BAY 1097761 further in Part B; this was not due to any safety data for BAY 1097761 (NCT04417036)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Adult-respiratory-distress-syndrome in Germany (Inhalation)
- 07 Jul 2020 Phase-II clinical trials in Adult respiratory distress syndrome in France, Spain (Inhalation) (NCT04417036)